Skip to content

Intrapartum Hydration

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01242293
Enrollment
300
Registered
2010-11-17
Start date
2010-11-30
Completion date
2015-08-31
Last updated
2016-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Stage, First, Labor Stage, Second

Brief summary

The purpose of this study is to determine that maternal hydration during labor with fluids containing glucose at a rate of 125 ml per hour does not affect the duration of labor compared to Ringer Lactate at a rate of 250 ml per hour.

Detailed description

During labor it is a common practice that the parturient is fastening and having fluid replacement through intravenous hydration (IVH), the rational being to avoid aspiration of gastric content in a situation of need for urgent intervention and general anesthesia with tracheal intubation. It is acceptable to infuse 125 ml per hour of a physiological solution that does not contain sugar, but the volume is not adjusted to the weight of mother, the level of effort or relaxation she is experiencing and it may well be below the required amount. From studies in the field of sport medicine it is clear that the amount of fluid reaching the muscle has an impact on the efficiency of the muscle at the level of tissue and the level of personal achievement in sports. Only few studies dealt with the amount and contents of IVH during labor that will be sufficient and meet all physiologic requirements of the parturient and her fetus.

Interventions

OTHER0.9% Saline with glucose 5%

intravenous hydration at a rate of 125 ml per hour during labor

OTHERRinger lactate

intravenous hydration at a rate of 250 ml per hour during labor

OTHERRinger lactate - Controls

intravenous hydration at a rate of 125 ml per hour during labor

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Nulliparous women * Gestational age 37-41 weeks * Cervical dilatation 1-3 cm * Vertex presentation * Singleton

Exclusion criteria

* Diabetes * Preeclampsia * Intra uterine fetal growth restriction * Duration of labor less than an hour * Maternal chronic disease * Maternal fever upon admission.

Design outcomes

Primary

MeasureTime frame
Length of time from enrollment until deliverywithin the first 48 hours after delivery

Secondary

MeasureTime frame
Mode of deliverywithin the first 48 hours after delivery
Neonatal outcomewithin the first 48 hours after delivery

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026